ImmunityBio

IBRX

Market cap $9.3B

ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties.

ImmunityBio Inc. (NASDAQ: IBRX) shares are up during Thursday's premarket session as the company has completed enrollment in its pivotal randomized trial evaluating Anktiva plus Bacillus Calmette-Guérin (BCG) against BCG alone for treating non-muscle invasive bladder cancer.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary tumors. The QUILT 2.005 trial (NCT02138734), which completed enrollment ahead of schedule,.

ImmunityBio Inc. (NASDAQ: IBRX) shares are down on Wednesday, cooling off from a huge up move as the company is reportedly experiencing significant revenue growth.

Source: Benzinga

On Feb. 23, 2026, investors weighed ANKTIVA's explosive revenue ramp against ImmunityBio's deep losses and ambitious global expansion.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (Nasdaq: IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, will participate as a featured speaker at "Cancer 2035: A Roadmap for the Future," a landmark summit co-hosted by the Milken Institute and the Richard Nixon Foundation in Washington, D.C. on February 23–24, 2026. T.

ImmunityBio's sales grew 700% in 2025, with fourth-quarter revenue rising 20% quarter over quarter. These excellent results extend an incredible run of good news for the up-and-coming biotech stock.

ImmunityBio Inc. (NASDAQ: IBRX) shares are up on Monday following the company's announcement of significant revenue growth.